Perspectives of Anti-Cancer Targeted Therapies
18 maggio 2012
Sede del Corso:
Domus Nova Bethlem - Roma
RAZIONALE
The rapidly changing scenario of diagnosis and therapy of cancer, due to the implementation of
highly refined molecular diagnostics and new generation sequencing techniques and to the
coming of a new wave of targeted agents, requires a timely, precise and expert update.
Aim of the course "Perspectives of Anti-Cancer Targeted Therapies" to be held in Rome, May 18, 2012 is to provide state of the art knowledge on all these topics. They will include: the most relevant signalling pathways and their role in cancer pathogenesis and in the onset of resistance to therapy, current and novel molecular diagnostic techniques, preclinical reliable mouse-human models to study significant molecular alterations and relative treatments, new therapeutic options in relevant types of cancer, challenges and new regulatory issues in early phase studies with new targeted agents.
The invited lecturers of the course are internationally acknowledged experts in all the above fields.
PROGRAMMA
8.30
Registration
9.00 - 11.00
Introduction
Giampaolo Tortora, Verona
Moderator: G. Tortora
EGFR targeting/ Lung cancer
Floriana Morgillo, Naples
HER-2 Targeting/ Breast
Sabino De Placido, Naples
K-ras/ Colon
Alberto Bardelli, Turin
11.00-11.30
Coffee Break
11.30-13.00
MAPK targeting and MEK inhibitors/ Pancreas
Michele Milella, Rome
New and existing targets of treatment in advanced prostate and renal neoplasia / Kidney and prostate
Sergio Bracarda, Arezzo
B-raf ecc/ Melanoma
Paolo Ascierto, Naples
13.00 - 14.00
Lunch
14.00-16.00
Moderator: S. Iacobelli
Genome sequencing and new strategies for future targeted therapies
Aldo Scarpa, Verona
New rules for early phase studies
Silvia Marsoni, Candiolo (Turin) – (Sostituto: Davide Melisi, Verona)
New strategies for trial design and biomarker discovery
Emilio Bria, Verona
16.00- 16.30
Discussion & Conclusions